Aktob: profile and news

тАЬWE HAVE BEEN CLOSELY EXAMINING THIS MARKET тАжтА? Oct 9, 2005
Vody, Balakov, Ufa, Cheliabinsk, Omsk, Novosibirsk, Nizhniy Novgorod, Kaliningrad, Kazan and Minsk (Belarus), Kishinev (Moldavia), Aktob, Astana, Aktau, Atyrau ... - Turkmenistan.ru, <**results**>

Children Who Have Lost Parents In Tsunami Disaster To Be Invited ... Jun 13, 2005
The Mediterranean Touristic Hotels Union (AKTOB), under the coordination of the Antalya Governor's office, has asked the Turkish Ministry of Foreign Affairs to ... - Turkish Press,

Turkey Draws Plan to Lure More Gulf Tourists Apr 30, 2005
The events in the resort city of Antalya were sponsored by Rixos Hotel, Turkish Airlines, Finansbank, AKTOB and dDf besides the ministry of tourism and Antalya ... - Middle East North Africa Financial Network,

Other information

Indication
For the treatment of pseudomonas aeruginosa lung infections

Pharmacology
Tobramycin, an aminoglycoside antibiotic obtained from cultures of Streptomyces tenebrarius, is used in combination with other antibiotics to treat urinary tract infections, gynecologic infections, peritonitis, endocarditis, pneumonia, bacteremia and sepsis, respiratory infections including those associated with cystic fibrosis, osteomyelitis, and diabetic foot and other soft-tissue infections.

Mechanism Of Action
Tobramycin binds irreversibly to one of two aminoglycoside binding sites on the 30 S ribosomal subunit, inhibiting bacterial protein synthesis. Tobramycin may also destabilize bacterial memebrane by binding to 16 S 16 S r-RNA. An active transport mechanism for aminoglycoside uptake is necessary in the bacteria in order to attain a significant intracellular concentration of tobramycin.

Drug Category
Anti-bacterial Agents; Aminoglycosides; ATC:J01GB01; ATC:S01AA12

Brand Names/Synonyms
3'-Deoxykanamycin B; Aktob; CHEMBANK2411; Distobram; Gernebcin; NF 6; Nebcin; Nebramycin; Nebramycin 6; Nebramycin Factir 6; Nebramycin Factor 6; Nebramycin Vi; Obracin; Obramycin; T4014; TOBRAMYCIN; Tenebrimycin; Tenemycin; Tobi; Tobracin; Tobradex; Tobradistin; Tobramaxin; Tobramitsetin; Tobramycetin; Tobramycin 98%; Tobramycin Base; Tobramycin Sulfate; Tobrasone; Tobrex

Dosage Forms
Ophthalmic Ointment; POWDER FOR SOLUTION; Solution for oral inhalation; Ophthalmic Solution; Oral Solution; IV Solution

Absorption
Not Available

Interactions
Interactions for Tobramycin:

In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME®, Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole.

Concurrent and/or sequential use of TOBI with other drugs with neurotoxic or ototoxic potential should be avoided. Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. TOBI should not be administered concomitantly with ethacrynic acid, furosemide, urea, or mannitol.

Chemical IUPAC Name
4-amino-2-[4,6-diamino-3-[3-amino-6-(aminomethyl)-5-hydroxy-tetrahydropyran-2-yl]oxy-2-hydroxy-cyclohexoxy]-6-(hydroxymethyl)tetrahydropyran-3,5-diol

Chemical Formula
C18H37N5O9

Half Life
Not Available

Drug Type
Approved Drug

# Accession No
APRD00582

CAS Registry Number
32986-56-4